|
FDA: One Patient’s Unique Experience Misleads on Efficacy in Novartis Aid
Novartis’ use of case studies in cancer drug Gleevec’s advertising material is misleading because one patient’s experience does not count as substantial evidence, the FDA says.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives